GLP toxicology study for adjuvanted HIV-1 immunogen vaccine candidates
Active Awarded Last action
- Contract number
- 75N93024F00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,428,706
Award facts
- Contract value 66% obligated
-
- $1,428,706.00 Current, with exercised options
- $2,154,144.00 Potential, with all options
- Completion date 45% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Exercise an Option | $714,077 | |
| Change Order | $0 | |
| Original award | $714,629 |
About this award
Sri International has been awarded a delivery order valued at $2.15M under the Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS) master indefinite-delivery/indefinite-quantity contract with the National Institute of Allergy and Infectious Diseases (NIAID). The award, issued on August 1, 2024, with an ultimate completion date of August 1, 2029, funds a Good Laboratory Practice (GLP) toxicology study for adjuvanted HIV-1 immunogen vaccine candidates. The contract is structured as cost-plus-fixed-fee and carries no small business set-aside designation. Work will be performed at Sri International's Menlo Park, California facility.
To support the toxicology study, Sri International has engaged Charles River Laboratories, Inc. as a major subcontractor for laboratory animal procurement and services, with that subcontract awarded on October 1, 2025. Charles River is a leading contract research organization specializing in providing laboratory animals and preclinical research services critical to vaccine development and safety evaluation efforts. This subcontract arrangement aligns with NIAID's mission to support advanced vaccine development through comprehensive preclinical safety and efficacy assessment, leveraging both Sri International's research and development capabilities and Charles River's specialized expertise in animal model provision and toxicology support services.
Quick answers
Who was awarded contract 75N93024F00001?
75N93024F00001 was awarded to Sri International by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2024.
How much is contract 75N93024F00001 worth?
The government has obligated $1,428,706 on 75N93024F00001. Its potential value, with all options, is $2,154,144.
Is contract 75N93024F00001 an order under another contract?
Yes. 75N93024F00001 is a delivery order under 75N93022D00007, an indefinite delivery contract, on Preclinical And Translational Vaccine Development For HIV And Other Candidate Agents.
Was contract 75N93024F00001 competed?
The extent of competition for 75N93024F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award